ZAYED-SUSTAINABILITY
15.3.2022 14:36:12 CET | Business Wire | Press release
The Zayed Sustainability Prize, the UAE’s pioneering global award for recognising organisations and high schools with sustainability solutions, has officially announced that the 2023 cycle is now open for submissions.
Entries will be accepted until 6 July 2022 through the Prize’s online portal. Small to medium enterprises, non-profit organisations and high schools with sustainability solutions are invited to submit an entry for consideration in one of the five categories of Heath, Food, Energy, Water and Global High Schools.
The Prize’s 2022 award cycle received a record-breaking 4,000 applications, marking a significant 68.5% increase in submissions compared to the previous cycle, from a record 151 countries.
Commenting on the launch of the 2023 submissions cycle, H.E. Dr. Sultan Ahmed Al Jaber, UAE Minister of Industry and Advanced Technology and Director General of the Zayed Sustainability Prize said: “For the past 14 years, the Prize has proudly delivered on its goal of recognising and rewarding the achievements of those who are driving impactful, innovative and inspiring sustainability solutions. As we continue to build on this legacy, we look forward to awarding the next cadre of sustainability pioneers, who will drive real environmental and social change and generate an even greater positive impact on the world.”
H.E. Al Jaber added, “Young people remain an integral focus for the Prize and we are committed to empowering even greater numbers of future sustainability leaders by providing them with a platform to turn their bold ideas into reality through our Global High Schools category.”
“The Zayed Sustainability Prize continues to be a steadfast partner and thought leader in international sustainable development. By amplifying the critical work being done globally in health, energy, food and water, and facilitating the delivery of these solutions to vulnerable communities around the world through the Prize winners, we have helped transform the lives of more than 370 million people.”
The Prize’s US$3 million annual fund rewards winners US$600,000 in each category. The Global High Schools category is split into six world region winners, with each school able to claim up to US$100,000 to start or further expand their project. The six world regions of the Global High Schools category are The Americas, Europe & Central Asia, Middle East & North Africa, Sub-Saharan Africa, South Asia, and East Asia & Pacific.
Inspired by the sustainability and humanitarian legacy of the UAE’s founding father, Sheikh Zayed bin Sultan Al Nahyan, the Prize has, to date, recognised a total of 96 winners whose solutions or student-led school projects have positively transformed the lives of millions.
While the submission forms vary per category, core elements of each entry lie in the innovative, impactful and inspirational ways in which the proposed technology, applications and solutions aim to transform people’s lives for the better.
For the Health, Food, Energy, and Water categories, organisations should demonstrate that they are improving access to essential products or services and have a long-term vision for improved living and working conditions. For the Global High Schools category, their projects should be student–led, with emphasis placed on the students being actively involved in the planning, implementation, and monitoring processes.
The Zayed Sustainability Prize has a three-stage evaluation process, beginning with the due diligence conducted by an independent research and analysis consultancy. This identifies the qualified entries and results in the selection of eligible candidates. Following this, evaluations are undertaken by a Selection Committee consisting of category-specific panels of independent international experts. From this shortlist of candidates, the finalists are chosen and then sent to the Prize Jury who unanimously elect the winners, across all five categories.
Winners will be announced in 2023 during an Awards Ceremony as part of the Abu Dhabi Sustainability Week (ADSW).
For more information, visit www.ZayedSustainabilityPrize.com
About the Zayed Sustainability Prize
Established by the UAE leadership, in 2008, to honour the legacy of the founding father, the late Sheikh Zayed bin Sultan Al Nahyan, the Zayed Sustainability Prize is the UAE’s pioneering global award for sustainability and humanitarian solutions around the world.
The Zayed Sustainability Prize recognises and rewards small to medium-sized enterprises (SMEs), non-profit organisations (NPOs), and global high schools, that are committed to accelerating impactful sustainable solutions.
Over the past 14 years, the Prize has awarded 96 winners. Collectively, they have positively impacted the lives of more than 370 million people around the world. The Zayed Sustainability Prize categories are Health, Food, Energy, Water and Global High Schools.
For more information, please visit www.ZayedSustainabilityPrize.com or go to our social media platforms on, Twitter , Facebook , Instagram , YouTube .
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220315005728/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
